Dr Rangan ChatterjeeDoctor SPEAKS OUT: "They're Quietly Labeling You Sick—Even When You're Not" | Suzanne O'Sullivan
Dr. Rangan Chatterjee and Dr Suzanne O'Sullivan on how modern medicine may over-diagnose, over-test, and reshape identity.
In this episode of Dr Rangan Chatterjee, featuring Dr. Rangan Chatterjee and Dr Suzanne O'Sullivan, Doctor SPEAKS OUT: "They're Quietly Labeling You Sick—Even When You're Not" | Suzanne O'Sullivan explores how modern medicine may over-diagnose, over-test, and reshape identity O’Sullivan distinguishes over-diagnosis from “wrong diagnosis,” arguing the core issue is whether medicalizing a struggle actually helps the person or simply burdens them with a patient identity.
At a glance
WHAT IT’S REALLY ABOUT
How modern medicine may over-diagnose, over-test, and reshape identity
- O’Sullivan distinguishes over-diagnosis from “wrong diagnosis,” arguing the core issue is whether medicalizing a struggle actually helps the person or simply burdens them with a patient identity.
- Through cases like a teenager labeled with a rare neurogenetic condition and a woman fearing Huntington’s disease, the conversation highlights how belief and attention can amplify symptoms (nocebo/labeling effects).
- They critique a “test-first” culture—scans, biomarkers, and screening—where incidental findings and broadened thresholds (e.g., blood pressure, pre-diabetes) can convert large populations into worried patients.
- The discussion explores controversial areas (autism/ADHD, cancer screening, POTS, long COVID communities) where labels may provide validation and support for some but reduce self-efficacy and expectations for others, especially children.
- Both emphasize “good medicine” as slower, relationship-based care—listening, follow-up, and clinical judgment—alongside a renewed role for generalists to counter harms from hyper-specialization and polypharmacy.
IDEAS WORTH REMEMBERING
5 ideasA diagnosis can be true and still be harmful.
O’Sullivan’s story of diagnosing 15-year-old Abigail with a rare neurodegenerative mutation shows that “finding something” may not help if there’s no treatment and the label changes how a healthy person experiences their body and future.
Labels change physiology indirectly by changing attention and interpretation.
The Huntington’s story (Valentina) illustrates how expecting illness can make ordinary lapses—tripping, airport stress—feel like evidence of decline, escalating anxiety and symptoms until the threatening interpretation is removed.
More testing creates more “abnormalities,” not necessarily more health.
Incidental findings on imaging (back scans, X-rays read as “arthritis”) and screening-detected abnormalities can trigger cascades of follow-up, worry, and treatment even when findings would never have caused harm.
Lowering thresholds medicalizes huge groups for small marginal gains.
They argue that expanding categories like borderline hypertension or pre-diabetes may prevent some events, but at the cost of turning many low-risk people into long-term patients—psychologically, financially (insurance), and medically (side effects).
Screening can save lives and still over-treat many others.
O’Sullivan cites screening trade-offs (e.g., breast cancer: many screened to save one life while more undergo unnecessary treatment) and stresses informed consent plus options like watchful waiting when appropriate.
WORDS WORTH SAVING
5 quotesOver-diagnosis doesn't mean the diagnosis was wrong. I had found something wrong with Abigail, but h- what favor had I done her really?
— Dr Suzanne O'Sullivan
I turned a girl who believed she was healthy into a patient.
— Dr Suzanne O'Sullivan
A diagnosis is not inert. It's not just something that comes with positives or neu- is neutral. It comes with negatives.
— Dr Suzanne O'Sullivan
Once you learn you have a disease, you can't unlearn it.
— Dr Suzanne O'Sullivan
I think we should be targeting people with multiple risk factors because we know that they're the high risk group, rather than targeting a whole population, including lots of people who have no other risk factors.
— Dr Suzanne O'Sullivan
QUESTIONS ANSWERED IN THIS EPISODE
5 questionsIn Abigail’s case, what practical criteria should clinicians use to decide whether to pursue genetic testing in minimally symptomatic children?
O’Sullivan distinguishes over-diagnosis from “wrong diagnosis,” arguing the core issue is whether medicalizing a struggle actually helps the person or simply burdens them with a patient identity.
How can doctors communicate scan findings (e.g., “degeneration,” “arthritis”) in ways that avoid nocebo effects while staying truthful and documented?
Through cases like a teenager labeled with a rare neurogenetic condition and a woman fearing Huntington’s disease, the conversation highlights how belief and attention can amplify symptoms (nocebo/labeling effects).
What would an “informed consent” conversation for cancer screening sound like if it genuinely covered over-diagnosis and over-treatment without deterring appropriate screening?
They critique a “test-first” culture—scans, biomarkers, and screening—where incidental findings and broadened thresholds (e.g., blood pressure, pre-diabetes) can convert large populations into worried patients.
If 27% of children receive school accommodations tied to medical labels, what alternative support model could help struggling kids without requiring a diagnosis?
The discussion explores controversial areas (autism/ADHD, cancer screening, POTS, long COVID communities) where labels may provide validation and support for some but reduce self-efficacy and expectations for others, especially children.
Where should the line be drawn between validating someone’s experience (e.g., autism/ADHD, long COVID, fibromyalgia) and reinforcing an illness identity that blocks recovery?
Both emphasize “good medicine” as slower, relationship-based care—listening, follow-up, and clinical judgment—alongside a renewed role for generalists to counter harms from hyper-specialization and polypharmacy.
Chapter Breakdown
From under-diagnosis to over-correction: why “more diagnosis” isn’t always better
Suzanne O’Sullivan frames the central argument of her book: medicine has corrected past neglect (e.g., learning needs, mental health, chronic disease) but may now be over-correcting. The conversation sets up the idea that rising diagnosis rates can reflect changing definitions and medical culture—not necessarily a sicker population.
What over-diagnosis actually means: “Is the diagnosis helping you?”
O’Sullivan clarifies that over-diagnosis is not “nothing is wrong,” but rather that a medical label may not be the most helpful response to genuine struggle. The emphasis shifts from diagnostic correctness to clinical usefulness and downstream consequences.
Case story: diagnosing a teen early—when a “true” diagnosis becomes a burden
O’Sullivan recounts diagnosing a rare genetic neurodegenerative condition in a patient (Stephanie) and then her seemingly healthy 15-year-old daughter (Abigail). Although clinically impressive and technically correct, she questions whether diagnosing Abigail so early improved her life—or unnecessarily turned her into a patient.
How labels change bodies: attention, nocebo effects, and symptom amplification
Using Abigail’s later reflection, the discussion explores how being told something is wrong can reshape bodily awareness. The core idea: diagnosis is not neutral—labels can intensify symptom monitoring and reinforce illness behaviors.
Huntington’s without the gene: when fear and expectation create “symptoms”
A powerful story follows Valentina, who learns her mother has Huntington’s and lives for years under the shadow of a 50/50 risk. She develops convincing symptoms—only to discover decades later her genetic test is negative, illustrating how belief and anxiety can shape experience.
Why “good medicine” is often slow: listening, follow-up, and selective testing
O’Sullivan and Chatterjee argue that high-quality care is not simply ordering tests; it’s careful history-taking, examination, time, and watchful waiting when appropriate. They discuss how language in reports (e.g., “degeneration,” incidental “arthritis”) can inadvertently harm patients.
System pressures: lost community supports, patient expectations, and label-dependent pathways
The conversation expands to societal and structural forces that push people toward medicalization. As community, family, and religious supports decline, doctors become default counselors—but the healthcare system often requires labels to unlock services.
Hyper-specialization and “diagnosis stacking”: when no one sees the whole patient
O’Sullivan critiques the fragmentation of modern care: clinicians narrowly focus on organs, subsystems, or single diseases. This can lead to multiple diagnoses explaining the same symptom and growing polypharmacy, without clear improvement in patient outcomes.
Lowering thresholds, expanding risk labels: blood pressure, pre-diabetes, and primary prevention trade-offs
They examine how changing cutoffs and “risk states” convert large parts of the population into patients. The key tension: prevention can help some, but may medicalize—and sometimes harm—many others through side effects, anxiety, costs, and identity shifts.
Cancer screening and over-treatment: why finding abnormal cells isn’t the same as saving lives
O’Sullivan explains how screening uncovers abnormalities that may never become dangerous. Because medicine can’t reliably distinguish indolent from aggressive disease early, screening can lead to overtreatment, anxiety, and invasive procedures for cancers that may never have mattered.
Autism’s expanding definition: support vs stigma, and what counts as “disorder”
They explore autism’s diagnostic evolution—from “extreme autistic aloneness” to a broad spectrum that now includes many mild presentations. O’Sullivan questions whether expanding criteria is improving downstream wellbeing, and highlights both the benefits (for severe disability) and harms (self-limiting beliefs, stigma) of labeling milder cases.
Genetics, AI, and direct-to-consumer testing: powerful tools with high misinterpretation risk
The discussion turns to modern diagnostic technology—genetic risk, BRCA, APOE4, and AI interpretation. O’Sullivan warns that tests developed in high-risk clinical groups can mislead when applied to the general population, and that consumer genetic testing can create false reassurance or unnecessary alarm—affecting entire families.
Illness identity vs recovery identity: community support that can trap people in symptoms
They examine how diagnoses can become identities, sometimes deepening symptoms and healthcare use. Stories include research on “engulfment” in cardiomyopathy and Paul Garner’s long COVID recovery journey, emphasizing that recovery often requires a believable future narrative—not constant symptom monitoring.
Closing message: preserve “any kind of future” through careful labeling and better consultations
O’Sullivan closes with a nuanced call: help people—especially young people—without unnecessarily shrinking their futures through premature or overly rigid labels. For clinicians, the main corrective is returning to core clinical skills: time, listening, whole-person thinking, and using technology to support (not replace) human care.
EVERY SPOKEN WORD
Install uListen for AI-powered chat & search across the full episode — Get Full Transcript
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome